Below are the most recent publications written about "Hydroxyurea" by people in Profiles.
-
Longoria JN, Pugh NL, Gordeuk V, Hsu LL, Treadwell M, King AA, Gibson R, Kayle M, Crego N, Glassberg J, Melvin CL, Hankins JS, Porter J. Patient-reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease. Am J Hematol. 2021 11 01; 96(11):1396-1406.
-
Rankine-Mullings A, Reid M, Soares D, Taylor-Bryan C, Wisdom-Phipps M, Aldred K, Latham T, Schultz WH, Knight-Madden J, Badaloo A, Lane A, Adams RJ, Ware RE. Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial. Br J Haematol. 2021 11; 195(4):612-620.
-
Estcourt LJ, Kimber C, Hopewell S, Trivella M, Doree C, Abboud MR. Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev. 2020 04 06; 4:CD012389.
-
Kwiatkowski JL, Voeks JH, Kanter J, Fullerton HJ, Debenham E, Brown L, Adams RJ. Ischemic stroke in children and young adults with sickle cell disease in the post-STOP era. Am J Hematol. 2019 12; 94(12):1335-1343.
-
Brousseau DC, Richardson T, Hall M, Ellison AM, Shah SS, Raphael JL, Bundy DG, Arnold S. Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children. Pediatrics. 2019 07; 144(1).
-
Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019 08 08; 381(6):509-519.
-
Shanbhogue P, Hoffmann RM, Airola MV, Maini R, Hamelin DJ, Garcia-Diaz M, Burke JE, Hannun YA. The juxtamembrane linker in neutral sphingomyelinase-2 functions as an intramolecular allosteric switch that activates the enzyme. J Biol Chem. 2019 05 03; 294(18):7488-7502.
-
Casella JF, Adams RJ, Brambilla DJ, Strouse JJ, Maier P, Dlugash R, Avadhani R, Vermillion K, Tonascia J, Voeks JH, Hanley DF, Thompson RE, Lehmann HP. Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease. Clin Trials. 2019 02; 16(1):20-31.
-
Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Doree C, Abboud MR. Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev. 2017 05 13; 5:CD012389.
-
Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017 07 15; 390(10091):311-323.